OT-A201 is a bispecific antibody for immuno-oncology to treat cancer patients.
What is a bispecific Antibody ?
A bispecific antibody is a protein capable of simultaneously binding to two different epitopes of the same or different antigens
Targeting two different antigens can enhance tumor selectivity and cell signaling interference
Bispecific antibody can serve as mediator to redirect immune effector cells to tumor cells
What could be OT-A201 therapeutic use ?
OT-A201 is targeting two immune checkpoints. It could help cancer patients in both onco-haematology and solid tumour indications.
OT-A201 was designed to enhance local tumor cell killing and counter tumor cells immune evasion through several mechanisms of action.
What are NK cells ?
Natural Killer (NK) cells are a type of lymphocytes and a component of the innate immune system, in which they play a major role in the host-rejection of both tumors and virally infected cells.
NK lymphocytes present natural cytotoxicity, as well as specific cytotoxicity in association with antibodies - Antibody Dependent Cell Cytotoxicity (ADCC).
What could be their therapeutic use ?
NK cells being highly potent immune effectors they are used alone as monotherapy, or in combination treatments with therapeutic antibodies, or are genetically engineered to produce Chimeric Antigen Receptor (CAR)-NK cells for the treatment of hematological and solid tumors.
NK-001 is an optimized cell therapy product consisting of highly activated & alloreactive allogeneic NK cells. Its patented manufacturing process allows full industrialization using the same batch of NK cells for many patients.